EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Altered dimerization of certain riboflavin transporter 2 mutants: a possible source of UPR, altered calcium signalling and mitochondrial derangements in RTD2

Maria Tolomeo, Valentina Magliocca, Stefania Petrini, Alessia Nisco, Roberto Barbaro, Martina Lanza, Michela Piccione, Anna Maria Giudetti, Keith Massey, Lara Console, Cesare Indiveri, Katia Zanier und 5 weitere

Archives of Biochemistry and Biophysics · 2026

DOI: 10.1016/j.abb.2025.110675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026. Verfasst von Maria Tolomeo und 16 weiteren Autor:innen. Beteiligte Einrichtung: CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnology, Bari, Italy. Hauptthemen laut MEDLINE: Mitochondria, Membrane Transport Proteins, Calcium Signaling, Hearing Loss, Sensorineural. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cure RTD Foundation, Fondazione Bambino Gesù, Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Riboflavin transporter deficiency Type 2 (RTD2, OMIM #614707), formerly known as Brown-Vialetto-Van Laere Syndrome 2 (BVVLS 2), is a rare autosomal recessive neurodegenerative disorder caused by biallelic variants in the SLC52A2 gene, encoding for riboflavin transporter 2 (RFVT2). This transporter plays a critical role in flavin cofactor delivery, particularly in the brain. Clinically, RTD2 presents with progressive hearing loss, optic atrophy, muscle weakness, respiratory issues, and pontobulbar palsy. Current treatment involves high-dose riboflavin and other supplements. In this study we explored the molecular mechanisms behind RTD2, focusing on the dimerization of RFVT2 and the associated cellular stress mechanisms in patient-specific models. We demonstrated that RFVT2 exists as a homodimer and that pathogenic variants significantly impair its dimerization, which may contribute to the induction of ER stress. This hypothesis was supported by elevated levels of BiP, an ER stress marker, in patient iPSC-derived motor neurons. Similar findings were confirmed in patient-derived fibroblasts, where we also observed mitochondrial dysfunction and disrupted calcium signaling. Interestingly, no significant changes in FAD content were detected in both cell models, suggesting that proteotoxic stress may be a crucial pathogenic mechanism in RTD2, even in the absence of signs of FAD deficiency. FAD autofluorescence and FLIM measurements reinforce the occurrence of mitochondrial dysfunction in patient MNs. These findings provide insight into the pathogenic mechanisms of RTD2, highlighting the critical role of RFVT2 misfolding, ER stress, and mitochondrial dysfunction in this neurodegenerative disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaMembrane Transport ProteinsCalcium SignalingHearing Loss, SensorineuralBulbar Palsy, ProgressiveUnfolded Protein ResponseProtein MultimerizationMutationHumansFibroblastsEndoplasmic Reticulum StressInduced Pluripotent Stem CellsReceptors, G-Protein-Coupled

Stichwörter der Autor:innen

FADMetabolic FLIMRFVT2RiboflavinSLC52A2iPSC-derived motoneurons

Substanzen

Membrane Transport ProteinsSLC52A2 protein, humanReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnology, Bari, Italy.
  • Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy; Department of Science, University "Roma Tre", Rome, Italy.
  • Confocal Microscopy Core Facility, Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Department of Biosciences, Biotechnologies, and Environment, University of Bari Aldo Moro, Bari, Italy.
  • Department of Biological and Environmental Sciences and Technologies (Di.S.Te.B.A.), University of Salento, Lecce, Italy.
  • Cure RTD Foundation, Calgary, AB, Canada.

Förderung

  • Cure RTD Foundation
  • Fondazione Bambino Gesù
  • Ministry of Health

Zitieren

APA

Tolomeo, M., Magliocca, V., Petrini, S., Nisco, A., Barbaro, R., Lanza, M., Piccione, M., Giudetti, A. M., Massey, K., Console, L., Indiveri, C., Zanier, K., Bertini, E., Persichini, T., Compagnucci, C., Colella, M., & Barile, M. (2026). Altered dimerization of certain riboflavin transporter 2 mutants: a possible source of UPR, altered calcium signalling and mitochondrial derangements in RTD2. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2025.110675

Vancouver

Tolomeo M, Magliocca V, Petrini S, Nisco A, Barbaro R, Lanza M, et al. Altered dimerization of certain riboflavin transporter 2 mutants: a possible source of UPR, altered calcium signalling and mitochondrial derangements in RTD2. Archives of Biochemistry and Biophysics. 2026. doi:10.1016/j.abb.2025.110675

BibTeX
@article{Tolomeo2026,
  author = {Tolomeo, Maria and Magliocca, Valentina and Petrini, Stefania and Nisco, Alessia and Barbaro, Roberto and Lanza, Martina and Piccione, Michela and Giudetti, Anna Maria and Massey, Keith and Console, Lara and Indiveri, Cesare and Zanier, Katia and Bertini, Enrico and Persichini, Tiziana and Compagnucci, Claudia and Colella, Matilde and Barile, Maria},
  title = {Altered dimerization of certain riboflavin transporter 2 mutants: a possible source of UPR, altered calcium signalling and mitochondrial derangements in RTD2},
  journal = {Archives of Biochemistry and Biophysics},
  year = {2026},
  doi = {10.1016/j.abb.2025.110675}
}
Kostenlos starten →